Dashboard
Manage Tickers

ATRC AtriCure, Inc.

Nasdaq atricure.com


$ 35.54 $ 0.39 (1.11 %)    

Tuesday, 14-Oct-2025 12:47:21 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 602.23 $ 7.02 (1.18 %)
DIA $ 464.07 $ 7.00 (1.53 %)
SPY $ 665.17 $ 7.89 (1.2 %)
TLT $ 90.72 $ 0.09 (0.1 %)
GLD $ 381.85 $ 3.55 (0.94 %)
$ 35.6
$ 35.17
$ 35.50 x 27
$ 35.57 x 10
$ 35.18 - $ 35.90
$ 27.32 - $ 43.11
447,152
na
1.77B
$ 1.39
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 07-30-2025 06-30-2025 10-Q
2 04-30-2025 03-31-2025 10-Q
3 02-14-2025 12-31-2024 10-K
4 10-30-2024 09-30-2024 10-Q
5 07-31-2024 06-30-2024 10-Q
6 05-02-2024 03-31-2024 10-Q
7 02-16-2024 12-31-2023 10-K
8 11-02-2023 09-30-2023 10-Q
9 07-26-2023 06-30-2023 10-Q
10 05-03-2023 03-31-2023 10-Q
11 02-22-2023 12-31-2022 10-K
12 11-02-2022 09-30-2022 10-Q
13 08-03-2022 06-30-2022 10-Q
14 05-04-2022 03-31-2022 10-Q
15 02-17-2022 12-31-2021 10-K
16 11-04-2021 09-30-2021 10-Q
17 08-05-2021 06-30-2021 10-Q
18 04-28-2021 03-31-2021 10-Q
19 02-26-2021 12-31-2020 10-K
20 11-06-2020 09-30-2020 10-Q
21 07-29-2020 06-30-2020 10-Q
22 04-30-2020 03-31-2020 10-Q
23 02-24-2020 12-31-2019 10-K
24 10-31-2019 09-30-2019 10-Q
25 07-31-2019 06-30-2019 10-Q
26 04-26-2019 03-31-2019 10-Q
27 03-01-2019 12-31-2018 10-K
28 11-02-2018 09-30-2018 10-Q
29 08-02-2018 06-30-2018 10-Q
30 04-27-2018 03-31-2018 10-Q
31 02-28-2018 12-31-2017 10-K
32 11-02-2017 09-30-2017 10-Q
33 07-28-2017 06-30-2017 10-Q
34 05-05-2017 03-31-2017 10-Q
35 03-08-2017 12-31-2016 10-K
36 10-28-2016 09-30-2016 10-Q
37 08-05-2016 06-30-2016 10-Q
38 04-29-2016 03-31-2016 10-Q
39 02-29-2016 12-31-2015 10-K
40 10-30-2015 09-30-2015 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

needham-maintains-buy-on-atricure-raises-price-target-to-45
Needham Maintains Buy on AtriCure, Raises ...
07/30/2025 10:44:15

Needham analyst Mike Matson maintains AtriCure (NASDAQ:ATRC) with a Buy and raises the price target from $44 to $45.

why-lendingclub-shares-are-trading-higher-by-around-23-here-are-20-stocks-moving-premarket
Why LendingClub Shares Are Trading Higher ...
07/30/2025 09:41:46

Core News & Articles
12 Health Care Stocks Moving In Tuesday's ...
07/29/2025 21:06:19

atricure-raises-fy2025-adj-eps-guidance-from-055-050-to-039-034-vs-053-est-raises-fy2025-sales-guidance-from-517000m-527000m-to-527000m-533000m-vs-522898m-est
AtriCure Raises FY2025 Adj EPS Guidance fr...
07/29/2025 20:05:51

AtriCure (NASDAQ:ATRC) raises FY2025 Adj EPS guidance from $(0.55)-$(0.50) to $(0.39)-$(0.34) vs $(0.53) analyst estimate. Rais...

atricure-q2-adj-eps-002-beats-017-estimate-sales-136139m-beat-130171m-estimate
AtriCure Q2 Adj. EPS $(0.02) Beats $(0.17)...
07/29/2025 20:04:03

AtriCure (NASDAQ:ATRC) reported quarterly losses of $(0.02) per share which beat the analyst consensus estimate of $(0.17) by 8...

Core News & Articles
Earnings Scheduled For July 29, 2025
07/29/2025 08:32:31

atricure-completes-enrollment-in-left-atrial-appendage-exclusion-for-prophylactic-stroke-reduction-clinical-trial
AtriCure Completes Enrollment In Left Atri...
07/15/2025 12:05:21

Largest cardiac surgery device trial ever with 6,500 patients enrolled, this landmark trial evaluates the stroke reduction bene...

ubs-maintains-buy-on-atricure-lowers-price-target-to-58
UBS Maintains Buy on AtriCure, Lowers Pric...
04/30/2025 14:21:00

UBS analyst Danielle Antalffy maintains AtriCure (NASDAQ:ATRC) with a Buy and lowers the price target from $60 to $58.

jmp-securities-reiterates-market-outperform-on-atricure-maintains-60-price-target
JMP Securities Reiterates Market Outperfor...
04/30/2025 14:18:35

JMP Securities analyst Daniel Stauder reiterates AtriCure (NASDAQ:ATRC) with a Market Outperform and maintains $60 price tar...

14-analysts-assess-atricure-what-you-need-to-know
14 Analysts Assess AtriCure: What You Need...
04/30/2025 13:01:14

visa-to-rally-more-than-12-here-are-10-top-analyst-forecasts-for-wednesday
Visa To Rally More Than 12%? Here Are 10 T...
04/30/2025 11:37:48

needham-maintains-buy-on-atricure-lowers-price-target-to-44
Needham Maintains Buy on AtriCure, Lowers ...
04/30/2025 10:45:28

Needham analyst Mike Matson maintains AtriCure (NASDAQ:ATRC) with a Buy and lowers the price target from $51 to $44.

atricure-raises-fy2025-adj-eps-guidance-from-064-057-to-055-050-vs-066-est-affirms-fy2025-sales-guidance-of-51700m-52700m-vs-52279m-est
AtriCure Raises FY2025 Adj EPS Guidance fr...
04/29/2025 20:08:43

AtriCure (NASDAQ:ATRC) raises FY2025 Adj EPS guidance from $(0.64)-$(0.57) to $(0.55)-$(0.50) vs $(0.66) analyst estimate. Affi...

atricure-q1-adj-eps-014-beats-023-estimate-sales-12362m-beat-12292m-estimate
AtriCure Q1 Adj. EPS $(0.14) Beats $(0.23)...
04/29/2025 20:02:38

AtriCure (NASDAQ:ATRC) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate of $(0.23) by 3...

Core News & Articles
Earnings Scheduled For April 29, 2025
04/29/2025 08:32:27

atricure-earnings-preview
AtriCure Earnings Preview
04/28/2025 19:02:27

citizens-capital-markets-reiterates-market-outperform-on-atricure-maintains-60-price-target
Citizens Capital Markets Reiterates Market...
04/02/2025 15:05:09

Citizens Capital Markets analyst Daniel Stauder reiterates AtriCure (NASDAQ:ATRC) with a Market Outperform and maintains $60...

canaccord-genuity-maintains-buy-on-atricure-lowers-price-target-to-52
Canaccord Genuity Maintains Buy on AtriCur...
03/28/2025 11:30:08

Canaccord Genuity analyst William Plovanic maintains AtriCure (NASDAQ:ATRC) with a Buy and lowers the price target from $66 ...

jp-morgan-maintains-overweight-on-atricure-lowers-price-target-to-46
JP Morgan Maintains Overweight on AtriCure...
03/27/2025 14:23:00

JP Morgan analyst Lilia-Celine Lozada maintains AtriCure (NASDAQ:ATRC) with a Overweight and lowers the price target from $5...

needham-reiterates-buy-on-atricure-maintains-51-price-target
Needham Reiterates Buy on AtriCure, Mainta...
03/27/2025 11:17:25

Needham analyst Mike Matson reiterates AtriCure (NASDAQ:ATRC) with a Buy and maintains $51 price target.

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION